Movement Alert｜Veradermics Rises 5.65% in Regular Trading, Positive Oral Hair Loss Drug Data and Strong Cash Position

Market Focus10-10

On October 10, Veradermics rose 5.65% in regular trading, trading at $133.97/share, with Turnover of $64.689 million.

The company's lead candidate VDPHL01, an oral non-hormonal therapy for hair loss, recently reported positive trial results. Female Phase 2 data showed improvement rates up to 90.0% at six months with a favorable safety profile, while male Phase 2/3 trials met all primary and key secondary endpoints.

As of June 30, the company held $819.9 million in cash and marketable securities, which it expects will fund operations into 2030, covering multiple Phase 3 readouts and the potential commercial launch of VDPHL01.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment